CHR-P programme
NWPharmaTech’s clinical high-risk for psychosis (CHR-P) programme is investigating NWPT-SM32300 — an investigational CBD micellar-emulsion softgel — with Professor Scott Woods as programme lead.
Investigational — effectiveness in this population has not been established.
Image caption: Conceptual animation of neural tissue and cell-membrane receptors (a still image when motion is off) — illustration only; not evidence of a mechanism, of brain delivery or of clinical benefit.
Start here
What the programme has done, what it plans and what is still unknown, with the source behind each statement.
Open the Programme Room
For investigators and research teams: public information with sources and limitations, an agenda of points to discuss, and a printable brief. No account is needed to explore the information or prepare a brief.
Explore a research collaboration
Plain-language planning for the CHR-P programme — informational only, not an offer to invest, a prospectus, or open subscription.
Read the funding overviewYou cannot invest, pay, or connect a wallet on our website.
Exploratory conversation only. Not an offer, and not a programme-updates registration.
Programme news only. Not required in order to express interest in financing, and not a request for health information.
Programme brief
Mission, clinical need, the investigational candidate, evidence status, roadmap and governance — an informational overview for visitors, collaborators and press. Not an offering document. Not medical advice.
Background
CHR-P is not a diagnosis of schizophrenia. An updated meta-analysis estimated that about one in four people identified as CHR-P (pooled estimate, 25%) developed psychosis within three years; most do not (Salazar de Pablo et al., 2021). NICE does not recommend antipsychotics to prevent psychosis in this group.
Read the clinical need explainer
Psychiatry & evidence: what clinical high risk means, what current care offers and what studies have found. Understanding cannabinoids: how CBD, THC and cannabinoid medicines differ. Both routes separate what is known from what remains open.
Explore the scienceImages are conceptual illustrations — not evidence of mechanism, delivery or clinical benefit.
Current programme
Status: planned Phase 2B · not recruiting · investigational
Investigational NWPT-SM32300 (300 mg CBD micellar-emulsion softgel) in people at clinical high risk: dose response, symptoms, safety and tolerability — approximately 328 participants, 12 weeks + week 16 follow-up. Effectiveness has not been established. Prevention is not the current primary aim.
Scientific leadership
Programme scientific leadership for CHR-P and related psychiatric development. Roles are individual scientific and company roles — not institutional endorsements of this website or any financing vehicle.
CHR-P programme lead Individual capacity
Clinical high-risk-for-psychosis expertise supporting early identification, assessment, and intervention research. Yale University does not sponsor or endorse this website, the DAO, or any financing vehicle.
Partner & Chief Scientific Officer
Company scientific leadership for NWPharmaTech’s research and development agenda, including the investigational CHR-P candidate.
Lead — Schizophrenia Programme
Senior psychiatric leadership for the company’s schizophrenia development strategy and clinical programme.
Updates
Educational notes on the science and proposed approach — not announcements of new clinical results or fundraising totals.
Programme news
Plain-language overview of the proposed design — not a results announcement.
Published 21 September 2026
Explainer
What the CHR-P workstream is designed to learn — and what remains open today.
Published 20 September 2026
Programme news
Why conventional biotech finance often struggles with CHR-P timelines — and the platform path under evaluation.
Published 20 September 2026Funding overview
We are evaluating a platform-supported route for eligible investors to help finance the CHR-P research programme, including a permissioned digital record of participation at closing where that proves feasible. If a platform path cannot meet legal, operational or investor-access requirements, a conventional private placement with a legal investor register remains the fallback. These are development objectives, not live offering terms. Neither path is available on this website: production investment, payment and token issuance remain inactive. Community updates and discussion are separate from any regulated investment process.
Any ~US$10 million figure is a planning target only — not money already raised, and not a claim that catalytic capital fully funds the Phase 2B programme.
